PFIZER INC.

The Global Antimicrobial Peptides Market is projected to grow from US$223.90 Mn in 2023 to US$532.02 Mn by 2031, driven by biotechnology advances and health awareness. Key players include Novozymes A/S, Pfizer Inc., and GlaxoSmithKline plc. Challenges include stringent regulations and microbial resistance.

The global Duchenne muscular dystrophy market was valued at US$2.2 billion in 2023 and is projected to grow at a CAGR of 11.7% to reach US$7.4 billion by 2034, driven by advancements in gene therapy, novel treatment approvals, and increased awareness.

Pfizer's IBRANCE, a CDK4/6 inhibitor, extended progression-free survival by 15 months in metastatic breast cancer patients when combined with anti-HER2 therapies. IBRANCE, initially approved in 2015, is the first treatment of its kind to show benefit in HR+, HER2+ metastatic breast cancer.

Clesacostat tromethamine + Ervogastat, targeting MASH with liver fibrosis, expected to generate $16 mn by 2036 in the US. The rNPV model, considering phase transition success rate and likelihood of approval, provides a risk-adjusted valuation. Pfizer, with revenues of US$58,496 mn in FY2023, develops and commercializes biopharmaceuticals globally.

The phase III PATINA trial showed palbociclib (IBRANCE®) plus standard-of-care maintenance therapy significantly improved progression-free survival (PFS) in HR+, HER2+ metastatic breast cancer patients, extending median PFS by over 15 months. Safety and tolerability were consistent with known profiles. Pfizer plans to discuss results with regulatory authorities.

Pfizer CEO Albert Bourla has withstood an ousting attempt by activist investor Starboard Value, despite Pfizer's declining share price. Starboard, with a $1 billion stake, blamed Bourla for the decline and claimed support from former executives. However, Bourla remains in control, attributed to Starboard's flawed analysis and Pfizer's potential hidden value in recent deals. Pfizer's Q3 2024 revenues rose 30%, further supporting Bourla's position.

Pfizer's Ibrance showed efficacy in HR+, HER2+ metastatic breast cancer, extending median progression-free survival by 50% in Phase III PATINA trial. This marks the first benefit shown by a CDK4/6 inhibitor in this patient group, representing about 10% of breast cancers. Ibrance, first approved in 2015, generated $4.75 billion in 2023, while Novartis' Kisqali brought in $2.08 billion.

The PATINA trial results show palbociclib (IBRANCE®) plus standard-of-care maintenance therapy significantly improves progression-free survival in HR+, HER2+ metastatic breast cancer patients, extending median PFS by over 15 months. The study, sponsored by Alliance Foundation Trials, is the first large phase III to demonstrate CDK4/6 inhibition benefits in this patient group. Pfizer plans to discuss these results with regulatory authorities.

The Clinical Trials Market is projected to grow from US$483B in 2023 to US$886.5B by 2032, driven by personalized medicine, tech advancements, and chronic disease prevalence. North America leads, while Asia-Pacific grows rapidly. Key trends include AI, decentralized trials, and regulatory support for inclusivity and efficiency.

ICER's review found 5 of the 10 highest-priced U.S. drugs lacked new clinical evidence to justify price increases, costing payers $815M in 2023. ICER uses the GRADE approach to assess evidence quality, focusing on new, moderate- to high-quality evidence. Some drugs, like Keytruda, Imfinzi, and Opdivo, had price increases supported by new evidence from randomized control trials.